Foghorn Therapeutics (FHTX) Share-based Compensation (2019 - 2026)

Foghorn Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 11.48% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $10.1 million (down 11.19% YoY), while the FY2025 annual figure was $10.4 million, down 12.56% from the prior year.
• Share-based Compensation was $2.4 million for Q1 2026 at Foghorn Therapeutics, up from $2.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.6 million in Q1 2023 to a low of $2.2 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.2 million across 5 years, with a median of $3.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 81.43% in 2022, then fell 29.48% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2022, then declined by 19.31% to $3.1 million in 2023, then declined by 18.62% to $2.5 million in 2024, then decreased by 9.75% to $2.2 million in 2025, then advanced by 6.34% to $2.4 million in 2026.
• The last three Share-based Compensation figures came in at $2.4 million (Q1 2026), $2.2 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.